ARMS, the more aggressive form of RMS, is characterized by t(2;13)(q35;q14) or t(1;13)(q36;q14) translocations in many of the tumors which result in chimeric transcripts that fuse the 5′ DNA binding domain of PAX3 or PAX7, respectively, to the transactivation domain of a forkhead transcription factor, creating novel PAX3/7-FOXO1 fusion proteins [2,3]. This evidence concerns the gene PAX3 and alveolar rhabdomyosarcoma.